Results for the Quarter Ended September 30, 2025 and Other Recent Highlights: Net investment income per share for the quarter was $0.38, compared to $0.39 for the quarter ended June 30, 2025Net asset value per share as of the end of the quarter was $14.66, compared to $14.75 as of June 30, 2025, a decrease of 0.6%New investment commitments made during the quarter totaled $138 million(1)Gross fundings, excluding revolver fundings,(2) totaled $142 million for the quarterThe Company received a net repayment of ...

Reports Revenue of $313.3 Million, Reflecting 9.3% Growth Raises Full Year Guidance to Reflect Continued Strength in Member Engagement Selling Season Yields Over 80 New Clients, 900,000 New Lives, and Near 100% Retention of Existing Base Record $156.0 Million in Operating Cash Flow Generated over the First Nine Months of 2025 Board Authorizes Up to $200 Million in Share Repurchase Program NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) ("Progyny" or the "Company"), a global leader i ...

Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. "We delivered another strong quarter with 98% revenue growth year-over-year, expanded gross ...

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer. " As we look forward to the remainder of 2025 and prepare for 2026, w ...

–Delivered Net Revenue of $80.5 Million––Gross Margin Improved to 37.4%, a Year-Over-Year Increase of Nearly 120 Basis Points––Quarterly Net Income of $1.7 Million––Reported Adjusted EBITDA of $11.0 Million––Reiterating Full Year Revenue and EBITDA Guidance– SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Turtle Beach Corporation (Nasdaq: TBCH, the “Company”), a leading gaming accessories brand, today reported financial results for the third quarter ended September 30, 2025 and reiterated full year guidance fo ...

Launched Akamai Inference Cloud, powered by NVIDIA AI infrastructure, to enable AI at the edge CAMBRIDGE, Mass., Nov. 6, 2025 /PRNewswire/ -- Akamai Technologies, Inc. (NASDAQ: AKAM), the cybersecurity and cloud computing company that powers and protects business online, today reported financial results for the third quarter ended September 30, 2025. "Akamai delivered a strong quarter, with solid top-line performance and excellent bottom-line results – highlighted by outperformance on margins and significan ...

核心业务进展 - 主要候选药物aleniglipron（GSBR-1290）作为每日一次口服小分子GLP-1受体激动剂，其针对肥胖或超重患者的ACCESS和ACCESS II两项研究预计在2025年底前获得36周顶线数据结果[1][2][3] - 除了主要研究外，公司正在进行三项补充研究以增强aleniglipron的竞争定位并支持三期项目设计，包括一项评估从已获批注射用GLP-1受体激动剂转换至aleniglipron的维持策略研究、一项评估身体成分变化的研究以及一项在2型糖尿病合并肥胖/超重患者中的研究[3] - 在胰淀素受体激动剂领域，公司计划在2025年底前启动ACCG-2671的一期临床研究，并已选定第二个开发候选药物ACCG-3535，临床前数据显示其作为单药或与司美格鲁肽联用均能有效减重[1][4][11] 财务状况 - 截至2025年9月30日，公司拥有现金、现金等价物及短期投资总额为7.990亿美元，预计现有资金可支持其运营及关键临床里程碑至少至2027年[1][5] - 2025年第三季度研发费用为5900万美元，较2024年同期的3260万美元增长81%，主要由于临床试验成本、临床前研发费用及员工费用增加以支持GLP-1R产品线进展[6] - 2025年第三季度净亏损为6570万美元（包含750万美元非现金股权激励费用），而2024年同期净亏损为3400万美元（包含600万美元非现金股权激励费用）[8][13] - 2025年第三季度总营业收入为7378.7万美元，相比2024年同期的4583.6万美元增长61%[13]

Aggregate Subscriber Value of $1.6 billion in Q3, 10% growth year-over-year Contracted Net Value Creation of $279 million, 35% growth year-over-year Net change in cash and restricted cash of $144 million and Cash Generation1 of $108 million in Q3, the sixth consecutive quarter of positive Cash Generation Cash Generation guidance for 2025 of $250 million to $450 million narrowed within original range, $350 million midpoint reiterated SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), Amer ...

BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced that it will be exhibiting at MEDICA 2025 in Düsseldorf, Germany, November 17-20, 2025. MEDICA is one of the largest and most ...

LAS VEGAS, Nov. 6, 2025 /PRNewswire/ -- Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the third quarter ended September 30, 2025. Operating revenues were $1.83 billion for the third quarter of 2025, an increase of $140.4 million from $1.69 billion for the third quarter of 2024. Net income attributable to Wynn Resorts, Limited was $88.3 million for the third quarter of 2025, compared to net loss attributable to Wynn Resorts, Limited of $32.1 mill ...